precision medicine

“Clinical trial design, cost, regulatory burden and recruitment are some of the challenges associated with clinical research,” said Victor J. Dzau, M.D., president, National Academy of Medicine and Research!America board member. Dzau joined other experts in basic science, clinical and translational research and patient advocacy to explore developments in clinical research during a Research!America Capitol Hill Briefing titled “Innovation Intersection” on June 12, 2017. “We must look at ways to leverage technology and utilize data sharing to make [clinical research] more efficient,” Dzau said. “And, of course, it’s important to shift towards looking at segments of the population, instead of...
The more researchers know about how different therapies work and for whom they work, the faster they can make progress in finding treatments, said Dr. William Nelson, director of Johns Hopkins Kimmel Cancer Center during a panel discussion on March 8 about precision medicine moderated by The Washington Post’s Laurie McGinley. The discussion was part of Johns Hopkins Medicine’s On the Road to Precision Medicine Health Care Leader Series , which explores topics of cost, communication, research, and health care delivery in relation to precision medicine. Regarding concerns that the drug approval process is too lengthy, Nelson said that the efficiency achieved by focusing on creating targeted...
Research and development involves collaboration, investments and risk to ensure new treatments benefit patients, according to panelists at a Capitol Hill briefing on February 14 hosted by Research!America and the Congressional R&D Caucus. The briefing “Medical Innovation 101” highlighted various aspects of the research continuum from basic to post-market research. Eleanor Perfetto, Ph.D., MS, of the National Health Council moderated the discussion, which included panelists representing different areas of the medical research continuum: basic science, clinical and translational research, health services research and health economics and the patient community. Keith Yamamoto, Ph.D., Vice...
The American Association for Cancer Research (AACR) has released the annual Cancer Progress Report , highlighting advances in cancer research, as well as advocating for sustained and robust funding for federal health agencies. AACR also hosted a congressional briefing on the progress report on Wednesday, September 21 to bring to Congress’ attention the importance of funding for research and emphasized patient involvement in moving research forward. Patient participation in clinical trials is important not only to test the efficacy of cancer drugs, but also to further the precision medicine initiative that aims to individualize cancer treatment based on each patient’s genetic code and...
As the population ages, is it possible to prevent, intercept and delay the onset of disease to live not only longer but expand the healthy period of life? Academic and industry experts discussed the concept of immorbidity - a perspective on medicine in which the priority shifts from treating or curing diseases like cancer and Alzheimer's to preventing, intercepting and halting the progression of disease -- at a session titled "Lifespan or Healthspan: Is it Time for a Paradigm Shift?" at the BIO International Convention on Wednesday, June 8. Dr. Keith Yamamoto, executive vice dean of the School of Medicine at the University of California, San Francisco and Dr. William N. Hait, global head of...
Dear Research Advocate: I’m pleased to announce that Senator Amy Klobuchar (D-MN) will be giving remarks at our Annual Meeting on March 16 at noon at the Willard Intercontinental Hotel. We will also be hearing from newly confirmed FDA commissioner Dr. Robert Califf and ALS patient advocate Lorri Carey. I hope you’ll join us at the annual meeting as well as at the Annual Advocacy Awards Dinner that evening. See our ad in Roll Call . Senators Patty Murray (D-WA) and Elizabeth Warren (D-MA) were joined by the eight other democratic members of the Senate HELP Committee today as they introduced the National Biomedical Research Act . This bill would provide a new mandatory funding stream for NIH...
As 2015 comes to an end, let’s revisit the top ten most popular Research!America blog posts of the year (based on page views) that emphasized the importance of communicating the value of research and making research and innovation a higher national priority. We would like to thank our outstanding guest bloggers, including early career scientists, and leaders representing academia, industry, patient groups and scientific societies, who believe in the endless possibilities of scientific discovery, development and delivery to improve our nation’s health. 1) Lessons learned from a workshop on effective science communication April 24 : Our most popular post of the year! Debra Cooper, Ph.D., a...
The National Institute of Health National Cancer Institute (NCI) has launched a new trial called MATCH, Molecular Analysis for Therapy Choice, in an effort to find new treatments for various forms of cancer. Announced at the annual meeting of the American Society of Clinical Oncology (ASCO) on June 1, the NCI-MATCH trials will try to determine whether targeted therapies for individuals with particular tumor gene mutations will be effective, regardless of cancer type. According to a press release by the National Institutes of Health, the NCI-MATCH trial will incorporate more than 20 different study drugs or drug combinations, each targeting a specific gene mutation, in order to match each...
Precision medicine is yielding promising results in treatments of certain diseases, including cancer and cystic fibrosis. It takes a greater and sustained national commitment to accelerate progress that accounts for individual variability in the genes, environment, and lifestyle of each person, and move the concept into clinical practice to benefit more patients. One such commitment has been made by President Obama through the Precision Medicine Initiative, with a $215 million investment in the President’s FY16 Budget. One immediate goal of the Initiative is to significantly expand efforts in cancer genomics to shape the development and use of some cancer treatments. The NIH Innovation Fund...
Large medical centers across the U.S. are investing in a burgeoning area of healthcare for their cancer patients: €œprecision medicine. Substantial investments are being made to not only build new laboratory facilities and purchase research equipment, but also to staff these new facilities. Universities like Weill Cornell Medical College , Harvard Medical School , and Johns Hopkins University are joining clinical centers like Memorial Sloan-Kettering Cancer Center in building an infrastructure for personalized medicine with the hope of playing a bigger role in the development of new drugs. This approach is building off of years of federal investment in genomics research. First, the Human...

Sidebar Quote

Without continued support for health research, many of the most promising young scientists, their ideas and a myriad of potentially life-changing scientific breakthroughs will vanish into oblivion.
Paul Marinec, PhD; University of California San Francisco